

## REMARKS

The specification has been amended to insert the sequence listing into the specification, in compliance with the requirements of 37 C.F.R. §§ 1.821-1.825.


Figures 2A and 2B, 6A and the specification have also been amended to insert the appropriate Sequence Identification Numbers (SEQ ID NOs) for the sequences listed in the accompanying sequence listing. No new matter has been introduced by this amendment.

## CONCLUSION

Applicants believe that no fee is due with this submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Attorney Reference No. 18475-034 (NEMC-215).

Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529  
Barry J. Marenberg, Reg. No. 40,715  
Attorney for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: November 13, 2001

Version with markings to show changes made

**In the Specification:**

Paragraph beginning on page 40, line 1 has been amended as follows:

-- N-terminal hydrophobic residues from the TM5 helix were then replaced with a palmitate lipid (C<sub>16</sub>H<sub>31</sub>O) to drastically reduce the size of the i3 peptides. Palmitoylated peptides were synthesized by standard fmoc solid phase synthetic methods with C-terminal amides. Palmitic acid was dissolved in 50% N-methyl pyrrolidone/50% methylene chloride and coupled overnight to the deprotected N-terminal amine of the peptide. After cleavage from the resin, palmitoylated peptides were purified to >95% purity by C18 or C4 reverse phase chromatography. As shown in FIG. 1B, the palmitoylated i3 loop peptide, P1pal-19 causes a rapid Ca<sup>2+</sup>i transient that is identical in profile to that caused by the extracellular PAR1 ligand, SFLLRN (SEQ ID NO:32). In addition, P1pal-19 fully activates platelet aggregation (FIG. 1D) with an EC<sub>50</sub> of 8 ± 3 micromolar. Individual aggregation traces of platelets stimulated with 10 Micromolar of indicated peptides or palmitic acid and platelet aggregation was monitored as % light transmittance of stirred platelets at 37 °C as described (L. Covic, A. L. Gresser, A. Kuliopoulos, *Biochemistry* 39, 5458-5467 (2000)). P1pal-19 completely inhibits the subsequent Ca<sup>2+</sup>i response to 30 micromolar SFLLRN (SEQ ID NO:32) (FIG. 1C) due to desensitization of PAR1. Similarly, prestimulation with SFLLRN (SEQ ID NO:32) completely desensitizes the platelets to P1pal-19. Palmitic acid by itself has no effect on Ca 2+i and platelet aggregation (FIG. 1B, D).--

Paragraph beginning on page 42, line 25 has been amended as follows:

-- PAR1-Rat1 cells or PAR2-COS7 cells were challenged with 1 nM to 10-100 ?M i3 peptide or mastoparan (INLKALAALAKKIL) (SEQ ID NO:33). PLC-beta activity was determined by measuring total [<sup>3</sup>H]-inositol phosphate (InsP) formation. As shown in FIG. 2B and C, P1pal-19, and P1pal-13 which lacks the N-terminal six residues of P1pal-19, stimulate InsP production with EC<sub>50</sub> values of 180 ± 20 nM and 700 ± 50 nM, respectively, and with similar efficacies as the natural agonist thrombin. In B and C, PLC-? activity was converted to percent of the full response relative to 0.1 nM thrombin (100%) and plotted as a function of peptide concentration using a two-site equation that fit the biphasic activation and inhibition profiles. The full PAR1 thrombin responses for individual experiments were 7.6-fold for P1pal-13, 9.4-fold for P1pal-12 and P1pal-7, 12.4-fold for P1pal-19 and P1pal-19/Rat1 alone, 18-fold for P1pal-19Q, 12.4-fold for P1pal-19E and 9.5-fold for the mastoparan experiment. The minor stimulation of untransfected Rat1 cells (Rat1 alone) by P1pal-19 in C can be attributed to the endogenous rat PAR1 present in these fibroblasts since addition of SFLLRN (SEQ ID NO:32) causes similar stimulation in these untransfected cells (FIG. 2F-'RAT1').--

Paragraph beginning on page 43, line 12 has been amended as follows:

-- The activation curves of PAR1 are biphasic with a steep activating phase followed by a steep inhibitory phase. Splitting the P1pal-19 agonist into C-terminal P1pal-7 and corresponding N-terminal P1pal-12 peptides results in loss of stimulatory activity in platelets or PAR1-Rat1 cells when added separately (FIGS. 1B, 1D, 2B) or together (FIG. 1B). Therefore, in order to have agonist activity, C-terminal PAR1 pepducin residues 301-313 must be contiguous. COS7 cells were transiently transfected with the human receptors PAR1, PAR2, PAR4, cholecystokinin A (CCKA), cholecystokinin B (CCKB), substance P (Sub-P), or rat somatostatin receptor (SSTR2). Transfected cells were challenged with a range of concentrations (0.1-10 micromolar) of P1pal-19, P1pal-13, or P2pal-21 and the highest stimulation of the individual receptors is reported as a black column. The extracellular agonists used to define maximum stimulation for each receptor (open column) were 10 nM thrombin for PAR1, 100 micromolar SLIGKV for PAR2, 100 nM thrombin for PAR4, 300 nM CCK-8 for CCKA and CCKB, 1 micromolar AGCKNFFWKTFTSC (SEQ ID NO:18) for SSTR2, and 1.5 micromolar RPKPQQFFGLM (SEQ ID NO:34) for Sub-P. The full activity profiles for P1pal-19 and P1pal-13 against these receptors are included as supplementary material (Supplementary information is available on *Science* Online at [www.sciencemag.org](http://www.sciencemag.org)).--

Paragraph beginning on page 46, line 20 has been amended as follows:

-- Next, to help distinguish between indirect versus direct activation of the G protein by the pepducins, a point mutation was introduced at position S309 located in the C-terminus of the i3 loop/N-terminus of TM6 of PAR1. This perimembranous region has been shown to be important for the fidelity of G protein coupling for many receptors S. Cotecchia, J. Ostrowski, M. A. Kjelsberg, M. G. Caron, R. J. Lefkowitz, *J. Biol. Chem.* 267, 1633-1639 (1992). ()E. Kostenis, B. R. Conklin, J. Wess, *Biochemistry* 36, 1487-1495 (1997); M. A. Kjelsberg, S. Cotecchia, J. Ostrowski, M. G. Caron, R. J. Lefkowitz, *J. Biol. Chem.* 267, 1430-1433 (1992). and comes into direct contact with the critical DRY residues of TM3 ()K. Palczewski *et al.*, *Science* 289, 739-45 (2000). A S309P mutant was constructed and transiently expressed in COS7 cells to the same level as wild type PAR1. COS7 cells were transiently transfected with wild-type (WT), S309P or delta377 PAR1 (A. Kuliopoulos *et al.*, *Biochemistry* 38, 4572-4585 (1999)) receptors. Cells were challenged with P1pal-19, SFLLRN (SEQ ID NO:32), or thrombin and PLC-beta activity determined by measuring total [<sup>3</sup>H]-inositol phosphate formation relative to 100% stimulation (9.6-fold) of WT PAR1 with 0.1 nM thrombin. The apparent inhibition of PAR1 by very high concentrations of thrombin in B is caused by persistent interactions of thrombin to a hirudin-like sequence (K51YEPF55) located in the e1 exodomain of PAR1 (D. T. Hung, T.-K. H. Vu, V. I. Wheaton, K. Ishii, S. R. Coughlin, *J. Clin. Invest.*

89, 1350-1353 (1992)). High amounts of thrombin can remain bound to the thrombin-cleaved PAR1 exodomain (S. L. Jacques, M. LeMasurier, P. J. Sheridan, S. K. Seeley, A. Kuliopoulos, *J. Biol. Chem.* 275, 40671-40678 (2000)) and inhibit intramolecular liganding by the tethered SFLLRN (SEQ ID NO:32).--

Paragraph beginning on page 47, line 15 has been amended as follows:

-- The S309P mutant is deficient in thrombin- and SFLLRN-dependent (SEQ ID NO:32) stimulation of InsP with 17- and 28-fold loss of potency, and 1.6- and 3.3-fold loss of efficacy, respectively (FIG. 3B, C). Interestingly, P1pal-19 also stimulates the S309P mutant with parallel losses in potency (13-fold) and efficacy (4.3-fold) relative to its effects on wild type PAR1 (FIG. 3A). Since P1pal-19 did not correct the signaling defect of the S309P mutation, this indicates that the crucial C-terminal portion of the i3 region in the intact receptor exerts dominant effects in coupling to G protein over that of the exogenous pepducin.--

Paragraph beginning on page 48, line 2 has been amended as follows:

-- To define the region(s) of the receptor that might directly contact the i3-pepducin, the entire C-terminal i4 domain of PAR1 was deleted (delta377). The X-ray structure of rhodopsin (K. Palczewski *et al.*, *Science* 289, 739-45 (2000)) indicates that the i3 loop may contact the N-terminal region of alpha-helix 8 and residues to the C-terminal side of the Cys-palmitate moieties within the i4 C-tail. As shown in FIG. 3B and C, the delta377 mutant is defective in stimulating PLC-beta in response to thrombin and SFLLRN (SEQ ID NO:32). Efficacy is reduced by 2-3 fold for the two PAR1 agonists and potency is shifted 22-fold for thrombin and ~30-fold for SFLLRN (SEQ ID NO:32). In contrast, the P1pal-19 pepducin gives effectively no stimulation of PLC-beta in the presence of the delta377 PAR1 mutant (FIG. 3A). These data demonstrate that the C-tail of PAR1 is required for P1pal-19 to activate G-protein and that the C-tail may provide a binding surface for the pepducin agonists.--

Paragraph beginning on page 49, line 2 has been amended as follows:

-- Human platelets were a convenient, biologically-relevant, system to test the potency and selectivity of anti-PAR1 and anti-PAR4 pepducins since platelets possess both PAR1 and PAR4 thrombin receptors with unique Ca<sup>2+</sup> signaling profiles (20). The PAR1 peptide, P1pal12, was found to completely block PAR1 signaling. Platelet Ca<sup>2+</sup> measurements were performed as in Example 1. Platelets were pre-treated with 3 ?M P1pal-12 (open arrow-head) or P4pal-15 (Pal-HTLAASGRRYGHALR (SEQ ID NO:9); closed arrow-head), and then stimulated with 3 Micromolar SFLLRN (SEQ ID NO:32) or 200 Micromolar AYPGKF (SEQ ID NO:35) as indicated. As shown in FIG. 4A-C, 3 micromolar P1pal-

12 effectively inhibits PAR1 activation of human platelets by SFLLRN (SEQ ID NO:32), but does not block PAR4 activation by AYPGKF (SEQ ID NO:35) (FIG. 4A). Moreover, a pepducin corresponding to the full-length i3 loop of PAR4, P4pal-15, had no agonist activity but was able to fully antagonize PAR4 signaling.--

Paragraph beginning on page 49, line 13 has been amended as follows:

-- Platelets were then preincubated with either 3 Micromolar P1pal-12 or 3 Micromolar P4pal-15 for 1 min and then challenged with 3 Micromolar SFLLRN (SEQ ID NO:32) or 200 Micromolar AYPGKF (SEQ ID NO:35) and platelet aggregation monitored as in FIG. 1D. Full platelet aggregation traces are also shown for the same amounts of SFLLRN (SEQ ID NO:32) or AYPGKF (SEQ ID NO:35) in the absence (-) of inhibitors. Platelets were pre-treated for 1 min with 0.01-5 Micromolar P1pal-12 or P4pal-15 and challenged with 3 Micromolar SFLLRN (SEQ ID NO:32) or 200 Micromolar AYPGKF (SEQ ID NO:35), respectively. As shown in FIG. 4A, 3 micromolar P4pal-15 blocked AYPGKF (SEQ ID NO:35) activation of PAR4 without affecting SFLLRN (SEQ ID NO:32) activation of PAR1 and is an effective inhibitor of platelet aggregation (FIG. 4B, C). Thus, P4pal-15 is the first described high-potency anti-PAR4 compound (IC<sub>50</sub> = 0.6 micromolar in platelets) and is currently being used to help delineate the role of PAR4 in the vascular biology of mice (Covic, Misra, Kuliopoulos, (unpublished data).).--

Paragraph beginning on page 49, line 25 was amended as follows:

-- Next, PAR1, PAR4, and PAR2-expressing fibroblasts were pre-treated with 0.03-100 micromolar P1pal-12, P4pal-15, or P2pal-21 for 5 min, and then challenged with extracellular agonists 0.1 nM thrombin, 10 nM thrombin, or 100 micromolar SLIGKV (SEQ ID NO:17), respectively. Percent InsP inhibition is calculated relative to the full extracellular agonist-stimulated response: 5.2-fold for P1pal-12, 3.1-fold for P4pal-15 and 3.1-fold for P2pal-21. Both anti-PAR1 and anti-PAR4 pepducins are also able to block signaling to PLC-beta in fibroblasts expressing PAR1 or PAR4, respectively (FIG. 4D). Lastly, the PAR2 pepducin, P2pal-21, which is a partial agonist for PAR2 (FIG. 2D), is also able to completely block PAR2 signaling in fibroblasts (FIG. 4D).--

Paragraph beginning on page 51, line 17 was amended as follows:

-- As an example, using NMR structural analysis, we have identified a region on the extracellular surface of PAR1 which forms part of the ligand binding site for PAR1. This region is comprised of receptor residues P85AFIS89 and is termed ligand binding site-1 (LBS-1). Mutation of this region on PAR1 results in severe defects in receptor activation by intermolecular ligand (i.e. SFLLRN (SEQ ID NO:32)) or thrombin. Addition of lipid-tethered peptides that mimic the receptor ligand binding site(s) might be

expected to interfere with thrombin-activated receptor (intramolecular ligand) or exogenously added intermolecular ligand (FIG. 8). Other extracellular loops of the receptor also likely make contact with the ligand and could contribute regions termed ligand binding site-2 (LBS-2), LBS-3, etc.--

Paragraph beginning on page 51, line 26 was amended as follows:

-- A receptor peptide (LBS1: PAFISEDASGYL-C) (SEQ ID NO:36) was synthesized that contains the P85AFIS89 sequence of PAR1 and adjacent C-terminal residues D90ASGTL95-C that are expected to come into close proximity with the lipid bilayer in the intact receptor (FIG. 9B). The non-lipidated LBS1 peptide was a relatively poor antagonist against thrombin and SFLLRN (SEQ ID NO:32) activation of PAR1-dependent platelet Ca<sup>++</sup> fluxes (FIG. 9C, and 9D, respectively). Likewise, the non-lipidated LBS1 peptide did not inhibit 3 nM thrombin aggregation of the platelets (FIG. 9E). In marked contrast, the C-terminally lipidated peptide, LBS1-PE (FIG. 9A) was an effective inhibitor of platelet aggregation. As shown in FIG. 9E, 25 micromolar LBS1-PE completely inhibited 3 nM thrombin-induced platelet aggregation.--

Paragraph beginning on page 53, line 2 was amended as follows:

-- Activation of the MC4 receptor (MC4R) by melanocortin agonists, such as melanocyte stimulating hormone (alpha-MSH) causes anorexia (loss of appetite) and weight loss in mice. Mutations of the MC4R have been found in extremely obese humans. Here, we synthesized a pepducin, MC4pal-14 (Pal-TGAIRQGANMKGAI) (SEQ ID NO:37) that corresponds to the third intracellular loop of the human MC4R, and tested the pepducin for agonist activity with its cognate receptor. Addition of MC4pal-14 to COS7 fibroblasts transiently transfected with MC4R stimulated adenylate cyclase activity by 35% relative to authentic agonist, alpha-MSH. The activity profile of MC4pal-14 is biphasic with an activating phase (EC<sub>50</sub>~150 nM) and inhibitory phase (IC<sub>50</sub>~10 micromolar). These data demonstrate that the pepducins can activate G<sub>S</sub>-coupled receptor pathways and that MC4pal-14 and its derivatives may have utility as anti-obesity agents in humans. Further, it is noteworthy that unlike systemically injected peptide agonists like alpha-MSH, these cell penetrating pepducins would be expected to cross the blood-brain barrier to activate receptors such as MC4 located in the central nervous system. (FIG. 7).--

## In the Drawings

Supplemental Table 1 has been amended as follows:

Supplemental Table 1. Agonist and Antagonist Activity of Pepducins for their Cognate Receptors Expressed in Fibroblasts.

Receptor stimulation of PLC- $\beta$  was determined by measuring total [ $^3$ H]-inositol phosphate (InsP) formation (15) in Rat1 cells stably expressing PAR1 or in COS7 cells transiently expressing PAR2, PAR4, SSTR2, CCKA, or CCKB. Antagonist assays were conducted as in Fig. 4D: PAR1, PAR2, PAR4, or SSTR2-expressing cells were pre-treated with their cognate pepducins (10 nM-50  $\mu$ M) for 5 min, and then stimulated with extracellular agonists 0.1 nM thrombin, 100  $\mu$ M SLIGKV (SEQ ID NO:17), 10 nM thrombin, or 1  $\mu$ M AGCKNFFWKTFTSC (SEQ ID NO:18), respectively. In agonist assays, PAR1, PAR2, PAR4, SSTR2, CCKA or CCKB-expressing fibroblasts were stimulated with their cognate pepducins (1 nM-50  $\mu$ M) for 30 min and InsP production measured. The biphasic pepducin data (see Fig. 2B-D) was fit to a two-site equation, with an EC<sub>50</sub> for the activating phase and IC<sub>50</sub> for the inhibitory phase (15). Percent efficacy was calculated relative to the full (100%) response to extracellular agonist as above (300 nM CCK-8 for CCKA and CCKB). NT = not tested.

Receptor	Pepducin	Sequence	SEQ ID NO	Antagonist IC <sub>50</sub> ( $\mu$ M)	Agonist EC <sub>50</sub> ( $\mu$ M)	Efficacy (%)
PAR1	P1pal-19	Pal-RCLSSAVANRSKKSRALF	1	-	0.18 $\pm$ 0.02	6.5 $\pm$ 1.0
	P1pal-13	Pal-AVANRSKKSRALF	2	-	0.70 $\pm$ 0.05	32 $\pm$ 5
	P1pal-7	Pal-KKSRALF	3	1.2 $\pm$ 0.1	-	-
	P1pal-12	Pal-RCLSSAVANRS	4	5.0 $\pm$ 1.0	-	-
	P1pal-19Q	Pal-RCLSSAVANQSOOSOALF	5	-	0.65 $\pm$ 0.1	30 $\pm$ 2
	P1pal-19E	Pal-RCESSAAEANRSKKERELF	6	$\geq$ 50	2.5 $\pm$ 0.5	80 $\pm$ 5
	P2pal-21	Pal-RMLRSSAMDENSEKKRRAIK	7	1.0 $\pm$ 0.5	0.018 $\pm$ 0.002	1.0 $\pm$ 0.2
	P2pal-21F	Pal-RMLRSSAMDENSEKKRRAIF	8	-	0.025 $\pm$ 0.003	7 $\pm$ 1
	P4pal15	Pal-HTLAASGRYYGHALR	9	3.0 $\pm$ 1.0	-	-
	P4pal15F	Pal-HTLAASGRYYGHALF	10	$\geq$ 2	-	-
PAR2	S2pal-23	Pal-KVKSSGIRVGSSKRKKSSEKKVTK	11	2.0 $\pm$ 1.0	-	-
	S2pal-23F	Pal-KVRSSGIRVGSSKRKKSSEKKVTE	12	3.0 $\pm$ 1.0	0.1 $\pm$ 0.05	0.5 $\pm$ 0.3
	Apal-19	Pal-RIRSSAANILMAKKRVR	13	NT	-	-
PAR4	Apal-19F	Pal-RIRSSAANILMAKKRVEF	14	NT	0.2 $\pm$ 0.1	2 $\pm$ 1
	Bpal-18	Pal-SGSRPTQAKLLAKKRVVR	15	NT	1.5 $\pm$ 0.5	10 $\pm$ 2
	Bpal-18F	Pal-SGSRPTQAKLLAKKRVVE	16	NT	0.10 $\pm$ 0.05	1.0 $\pm$ 0.5
SSTR2						13 $\pm$ 2
						12 $\pm$ 3
						11 $\pm$ 10
CCKA						15 $\pm$ 4
						12 $\pm$ 3
						10 $\pm$ 1
CCKB						13 $\pm$ 2
						12 $\pm$ 3
						11 $\pm$ 2